Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexDJIA S&P500 P/E19.92 EPS (ttm)12.24 Insider Own0.20% Shs Outstand588.00M Perf Week-1.57%
Market Cap143.01B Forward P/E14.47 EPS next Y16.85 Insider Trans-0.48% Shs Float584.66M Perf Month-2.54%
Income7.30B PEG2.90 EPS next Q3.80 Inst Own78.20% Short Float1.06% Perf Quarter4.72%
Sales24.30B P/S5.88 EPS this Y2.00% Inst Trans-0.69% Short Ratio2.39 Perf Half Y22.97%
Book/sh18.13 P/B13.45 EPS next Y6.85% ROA11.90% Target Price262.76 Perf Year24.79%
Cash/sh19.47 P/C12.52 EPS next 5Y6.87% ROE71.70% 52W Range177.05 - 264.97 Perf YTD1.14%
Dividend6.40 P/FCF21.69 EPS past 5Y14.00% ROI21.20% 52W High-7.98% Beta0.82
Dividend %2.62% Quick Ratio1.80 Sales past 5Y3.10% Gross Margin78.20% 52W Low37.71% ATR6.63
Employees23400 Current Ratio2.20 Sales Q/Q5.70% Oper. Margin37.90% RSI (14)47.27 Volatility2.95% 2.68%
OptionableYes Debt/Eq3.21 EPS Q/Q-14.70% Profit Margin30.00% Rel Volume1.00 Prev Close240.32
ShortableYes LT Debt/Eq3.20 EarningsJul 28 AMC Payout49.50% Avg Volume2.60M Price243.82
Recom2.20 SMA20-1.44% SMA50-1.13% SMA2005.14% Volume2,587,911 Change1.46%
Apr-15-20Resumed Guggenheim Neutral
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-30-20Upgrade Raymond James Mkt Perform → Outperform $255
Mar-05-20Upgrade BofA/Merrill Neutral → Buy $245 → $250
Feb-27-20Initiated Barclays Equal Weight $235
Jan-31-20Downgrade Robert W. Baird Neutral → Underperform $173 → $185
Jan-21-20Upgrade Evercore ISI In-line → Outperform
Dec-24-19Initiated Raymond James Mkt Perform
Dec-17-19Resumed Morgan Stanley Overweight $280
Nov-12-19Initiated SunTrust Buy $256
Nov-05-19Upgrade Cantor Fitzgerald Neutral → Overweight $230 → $255
Oct-17-19Resumed BofA/Merrill Neutral $215
Aug-19-19Downgrade Mizuho Buy → Neutral $208 → $212
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Outperform $208
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Sep-24-20 09:46AM  
Sep-22-20 03:45PM  
02:41PM  
Sep-21-20 10:42AM  
08:05AM  
06:31AM  
Sep-20-20 08:39AM  
08:25AM  
Sep-19-20 07:00AM  
Sep-18-20 04:16PM  
12:41PM  
Sep-17-20 04:31PM  
11:00AM  
09:37AM  
06:41AM  
06:30AM  
Sep-16-20 04:15PM  
04:00PM  
06:06AM  
Sep-15-20 11:53AM  
09:00AM  
Sep-14-20 04:00PM  
08:00AM  
06:25AM  
Sep-11-20 04:00PM  
09:45AM  
06:40AM  
Sep-10-20 03:18PM  
02:17PM  
Sep-08-20 01:58PM  
Sep-04-20 04:00PM  
06:59AM  
Sep-02-20 02:45PM  
12:12PM  
10:56AM  
06:00AM  
Sep-01-20 01:49PM  
12:00PM  
01:54AM  
12:09AM  
Aug-31-20 11:49PM  
08:11PM  
04:18PM  
03:17PM  
02:31PM  
01:33PM  
01:15PM  
11:34AM  
11:25AM  
11:21AM  
10:57AM  
10:20AM  
10:01AM  
Aug-29-20 08:15AM  
05:31AM  
Aug-28-20 01:51PM  
01:51PM  
05:01AM  
Aug-27-20 03:44PM  
11:31AM  
08:25AM  
Aug-26-20 12:42PM  
12:23PM  
09:27AM  
08:00AM  
06:11AM  
Aug-25-20 06:18PM  
05:28PM  
04:57PM  
04:56PM  
04:35PM  
04:22PM  
04:00PM  
04:00PM  
03:45PM  
03:06PM  
02:08PM  
01:23PM  
12:18PM  
11:25AM  
10:45AM  
10:22AM  
10:00AM  
09:41AM  
09:37AM  
09:15AM  
08:53AM  
08:33AM  
08:14AM  
07:47AM  
06:18AM  
04:04AM  
12:17AM  
Aug-24-20 11:13PM  
07:02PM  
06:23PM  
06:12PM  
05:46PM  
05:42PM  
Aug-21-20 08:00PM  
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; and Adaptive Biotechnologies. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorAug 19Option Exercise54.691,00054,69016,589Aug 19 06:00 PM
SUGAR RONALD DDirectorAug 19Sale241.021,000241,02015,589Aug 19 06:00 PM
Williams R SandersDirectorAug 07Sale242.9525060,7385,159Aug 10 05:42 PM
SUGAR RONALD DDirectorJul 22Option Exercise54.691,00054,69016,589Jul 22 06:11 PM
SUGAR RONALD DDirectorJul 22Sale259.791,000259,79015,589Jul 22 06:11 PM
SUGAR RONALD DDirectorJun 17Option Exercise54.691,00054,69016,576Jun 17 06:11 PM
SUGAR RONALD DDirectorJun 17Sale228.541,000228,54015,576Jun 17 06:11 PM
SUGAR RONALD DDirectorMay 20Option Exercise54.691,00054,69016,482May 20 09:24 PM
SUGAR RONALD DDirectorMay 20Sale229.271,000229,27015,482May 20 09:24 PM
Williams R SandersDirectorMay 06Sale237.31425100,8575,409May 07 08:49 PM
SUGAR RONALD DDirectorApr 22Option Exercise54.691,00054,69015,636Apr 22 07:07 PM
SUGAR RONALD DDirectorApr 22Sale233.351,000233,35014,636Apr 22 07:07 PM
Bradway Robert AChairman, CEO and PresidentApr 13Option Exercise58.43127,0007,420,610595,516Apr 13 07:54 PM
Piacquad DavidSVP, Business DevelopmentFeb 06Sale229.939,2642,130,07939,700Feb 07 08:25 PM
Williams R SandersDirectorFeb 06Sale233.7242599,3314,988Feb 10 09:33 PM
Meline David WEVP & CFONov 25Sale234.368,7372,047,60349,378Nov 25 06:27 PM
Graham Jonathan PEVP, Gen. Counsel & Secy.Nov 22Sale230.549,0002,074,83742,853Nov 25 06:25 PM
Piacquad DavidSVP, Business DevelopmentNov 20Option Exercise156.355,749898,85653,361Nov 20 08:09 PM
SUGAR RONALD DDirectorNov 06Option Exercise54.712,000109,42016,436Nov 07 06:20 PM
Williams R SandersDirectorNov 06Sale215.4542591,5665,413Nov 07 06:22 PM
SUGAR RONALD DDirectorNov 06Sale215.452,000430,90014,436Nov 07 06:20 PM
SUGAR RONALD DDirectorOct 02Option Exercise54.712,000109,42016,436Oct 03 05:06 PM
SUGAR RONALD DDirectorOct 02Sale193.582,000387,16014,436Oct 03 05:06 PM